Evaluation of a service reconfiguration for managing intravenous iron supplementation in non-haemodialysis patients with chronic renal failure

Journal of Outcomes Research

Volumn 8, Issue 15-25, 2004, Pages 15-25

  Peebles, George ^a   Stanley, Stewart ^b  

^a SUNDERLAND ROYAL HOSPITAL   (United Kingdom)

^b CP Healthcare Consultants   (United Kingdom)

Author keywords

Cost impact; Erythropoietin; Intravenous iron; Low molecular weight iron dextran complex; Renal services; Savings

Indexed keywords

COSMOFER; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; IRON DEXTRAN;

ANEMIA; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG EFFICACY; HEMODIALYSIS; HOSPITAL COST; HUMAN; IRON THERAPY; LIFESTYLE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; REVIEW;

EID: 3543095617     PISSN: 1369698X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrology, Dialysis, Transplantation 1999; 14 (Suppl 5): 1-13.
2. Renal Association. Treatment of adults and children with renal failure: standards and audit measures. 3rd edn. 2002; London: Royal College of Physicians of London and the Renal Association.
3. Vitaline Pharmaceuticals UK Ltd. CosmoFer® summary of product characteristics. April 2001.
4. Auerbach M, Winchester J, Wahab A et al. A randomised trial of three iron dextran infusion methods for aneamia in EPO-treated dialysis patients. American Journal of Kidney Diseases 1998; 31: 81-86.
5. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases 1995; 26: 41-46.
6. Senger JM, Weiss RJ. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment. ANNA Journal 1996; 23: 319-323.
7. Besarab A, Amin N, Ahsan M et al. Optimization of epoietin therapy with intravenous iron therapy in hemodialysis patients. Journal of the American Society of Nephrology 2000; 11: 530-538.
8. Park L, Uhthoff T, Tierney M et al. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients. American Journal of Kidney Diseases 1998; 31: 835-840.
9. Bhandari S, Brownjohn A, Turney J. Effective utilization of erythropoietin with intravenous iron therapy. Journal of Clinical Pharmacology and Therapeutics 1998; 23: 73-78.
10. Macdougall IC, Tucker B, Thompson J et al. A randomised controlled study of iron supplementation in patients with erythropoietin. Kidney International 1996; 50: 1694-1699.